Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Spondyloarthritis
What is your experience with using oral roflumilast for psoriatic arthritis?
Related Questions
What is your approach to differentiating tender spots (as in fibromyalgia) and enthesitis (as in axSpA)?
What is your approach to choosing a particular advanced therapy based on patient or disease factors when initiating treatment for moderate-severe IBD?
How would you manage axial stiffness without pain in an elderly gentleman with a distant history of HLA-B27+ axial and peripheral spondyloarthritis, now with SI joint fusion, no peripheral arthritis, normal inflammatory markers, and no response to TNF inhibition?
Do you generally attempt to taper and discontinue biologics in a patient with psoriatic arthritis who is in clinical remisson?
In a patient with isolated HLA B27+ anterior uveitis, how long would you continue immunosuppressive therapy?
What circumstances would drive you to consider using an oral IL-23 inhibitor over parenteral options for the management of psoriasis and/or psoriatic arthritis?
Would you choose bimekizumab over other IL-17 inhibitors in patients with increased levels of disease related pain and poor functional status?
Do you use biologic DMARDs for active axial spondyloarthritis in transplant patients on long-term anti-rejection therapy?
How would you treat a patient with psoriatic arthritis who developed disseminated histoplasmosis while on adalimumab and previously failed all non-biologic DMARDs?
Would you escalate treatment for a patient with Crohn disease with changes suggestive of chronic sacroiliitis on MRI but without bone marrow edema or effusion that suggests active inflammation?
